Cingulate Files FDA New Drug Application for Lead ADHD Drug CTx-1301
Cingulate Inc., a biopharmaceutical company specializing in next-generation pharmaceutical products through its proprietary Precision Timed Release (PTR) technology, announced it has…
Read More...
Read More...
